Pelvic floor disorders (PFDs) such as stress urinary incontinence (SUI) and pelvic organ prolapse (POP) are very common and extremely embarrassing. As many as one in five women seek surgery to try to regain a normal quality of life.; women are living longer and in the USA the prevalence of POP is projected to increase by 46% between 2010 and 2050 (REF. 1 ). Despite the un acceptably high revision and complication rates of current PFD treatments, attention to and funding for PFD research has been minimal.
On 16-17 October 2017, The Royal Society sponsored a workshop (https://royalsociety.org/science-events-andlectures/2017/10/pelvic-floor/) on tissue regeneration and re-engineering of female PFDs. At this meeting, surgeons and scientists discussed why progress has been so slow. By identifying gaps in our knowledge, we could then focus on identifying key questions
, the answers to which should improve the quality of life of millions of women.
Gloria Esegbona explained that, although these disorders occur within an integrated tract of tissues in the female pelvic region configured for reproduction, not all women who suffer maternal injuries of childbirth develop PFDs later in life. Do some have improved cap ability to regenerate damaged tissues and can we impart this capability to other women? Answering this question to improve outcomes for women is a challenge that needs immediate attention.
Our knowledge of the anatomy and physiology of the pelvic floor is incomplete and we still do not fully understand how the pelvic floor functions as it responds to the demands of childbirth and ageing. Pregnancy and delivery are initiating events for SUI and POP 2 ; however, although some women experience PFDs immediately after childbirth, most women develop SUI and POP around the time of menopause, when the childbirth-related injuries are compounded by ageing and contributing factors such as obesity and diabetes [3] [4] [5] . Part of the problem is fragmentation of the field -modern medicine is divided into silos of responsibility into which a condition that can take 20 years to develop does not fit neatly. Furthermore, during the past decade researchers have struggled to obtain funding to develop new materials, owing to refusal of some manufacturers of polypropylene (PPL) mesh to acknowledge that a problem exists. Finally, the problem has remained invisible because embarrassment has discouraged women from reporting SUI and POP. However, the severity of the side effects associated with the use of PPL mesh 6 are extreme enough that they overcome reticence and embarrassment, and women are now speaking out.
To predict who will experience the most damage from vaginal birth, James Ashton-Miller, Renato Natal Jorge, and Pedro Martins discussed how patients can be identified using clinical predictive data and computational models of how the pelvis functions during childbirth. Such models encompass mechanical and aetiological aspects of the development of female PFDs. In addition, both standard and novel materials can be introduced into such models to provide an in silico test of the benefits of new treatments before clinical trials. For example, widely accepted dogma states that PFDs arise from a defective vaginal wall. Ashton-Miller questioned this dogma as computational models suggest that defects in the paravaginal tissue, which can be corrected, might actually be the cause.
Marianna Alperin summarized how animal models show that pelvic floor muscles undergo unique adaptations in preparation for the supraphysiological strains that they encounter during childbirth. These adaptations attenuate sarcomere hyperelongation and protect against pelvic muscle injury, and could potentially act as an indicator of damage or a predictor of patients who might be most at risk of developing PFDs after vaginal delivery.
The extracellular matrix (ECM) is an important component of the pelvic floor and is dysregulated in patients with POP, such that the balance is tipped towards ECM degradation, reducing the strength and elasticity of the pelvic floor. Oksana Shynlova described how vaginal fibroblasts produce the ECM and are abnormal in patients with POP, such that they decrease ECM protein synthesis and increase expression of ECM degradation enzymes with stretch. Shynlova suggested that abnormal fibroblasts Repairing the female pelvic floor: when good enough is not good enough
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Women commonly experience pelvic floor damage during pregnancy and vaginal childbirth and later develop stress urinary incontinence and prolapse. Polypropylene mesh can repair abdominal hernias, but complications result when used in the female pelvic floor. In October, the Royal Society hosted a workshop to address issues surrounding pelvic floor disorders.
could provide an objective index of the degree of POP and the reparative capability of the pelvic floor.
Regeneration can be facilitated by treatment with stem cells either alone or as a supplement to an ECM or synthetic scaffold. Margot Damaser and J. Koudy Williams explained that the regenerative effect of stem cells is often via their secretions, raising the possibility of treating patients using cellular secretions or cell-derived materials 7 . The use of endometrium-derived cells is being explored by Caroline Gargett, whereas Damaser is testing whether cell-derived microsomes can stimulate tissue regeneration and prevent PFD development. The idea of early treatment before stage IV POP development was further explored by K. D. Sievert who compared delayed therapy with waiting until a tumour progressed to stage IV to treat cancer.
Sheila MacNeil reminded workshop attendees of a 2017 consensus statement 8 written by gynaecologists, urologists, and urogynaecologists, which concluded that surgeons are probably performing the right type of operation, but with a suboptimal material. This observation raises the question of which materials surgeons should use and, indeed, some experienced surgeons have reverted to using patients' native fascia when available. The consensus statement concluded that patients with PFDs need new materials without severe adverse effects 8 . Three groups at the workshop reported development of next-generation materials for the repair of PFDs. The approach discussed by Stephen Badylak and Pamela Moalli uses materials designed from acellular ECM. Badylak described how native collagenous tissues can be used to stimulate tissue regeneration rather than scar formation, introducing the fundamental role of the immune system in rejection or acceptance of foreign materials, potentially leading to tissue regeneration. Another approach, described by MacNeil, is based on a mesh of FDA-approved polyurethane fibres that respond well to repeated distension and are well tolerated by the immune system in animals 9 . A further option based on the use of recombinant human collagen combined with autologous cells derived from the patient's endometrium was proposed by Gargett.
How to introduce new materials was a great topic of discussion -newly designed biomaterials are rarely fully optimized when they are first developed; instead bio materials are designed and tested critically in the laboratory, eliminating materials that fail at that stage. Regulatory bodies normally require that animal models then be used to evaluate potential toxicity and efficacy. However, neither of these was addressed at the time of introduction of PPL mesh for repair of the female pelvic floor. Application for PFDs was instead justified based on its successful prior use in the abdominal muscle, a very different environment from the female pelvic floor with very different requirements and outcomes. Several groups are now working with animal models to test new materials. This type of study, more than any other, was needed but lacking when PPL meshes were introduced for use in the pelvic floor. Jan Deprest described his extensive experience developing animal models to study many aspects of POP and to evaluate materials before they are implanted into patients. Both he and Gargett are using sheep as a relevant and accessible model for evaluating material to be introduced into the vagina for PFDs. Deprest has shown that PPL meshes that do well in the abdomen cause PFDs when implanted in the vagina of the same animalsdefinitively demonstrating that the vagina is not the same environment as the abdomen 10 .
To conclude the meeting, Sohier El Neil reiterated that the field desperately needs collaboration between clinicians and scientists. Molecular and cellular effects of surgery need to be considered along with the systemic effects of treatments as scientific research is the foundation of personalized medicine. Increased awareness of the problem is needed, not only in scientific and clinical circles but also among the general public. For too long PFDs have been invisible -now it is time to own the problem and tackle it.
